Followers | 48 |
Posts | 3520 |
Boards Moderated | 0 |
Alias Born | 02/15/2009 |
Saturday, January 23, 2021 12:01:34 PM
Statistical Facts in Medical Science do matter!
BRILACIDIN SI *426*. Some keep babbling about safety.
Government RBLs recently declared BRILACIDIN has a SI of *426*.
Everyone was hoping to at least equal Gileads Remdesivir number of 129.87. A number good enough for FDA APPROVAL and 2 billion in revenues last year.
The higher the SI ratio the more EFFECTIVE and SAFE a drug would be during treatment for viral infections.
SAFE and EFFECTIVE are the key words.
The SI of a compound IS widely accepted parameter used to express a compounds efficacy in the INHIBITION of virus replication.
BRILACIDIN *426* efficiency has a 97% kill rate of the virus in lab testing. When combined with Remdesivir's 129 the kill rate did slightly jump up to 99.85%.
Simply put, peple would being saved at this very moment IF Gilead
was owner of BRILACIDIN *426*.
Seeing is believing. BRILACIDIN did so well that the RBLs STATED that BRILACIDIN should be lab tested against a host of other viruses.
You can believe what the major UNIVERSITIES, Government RBLs and highly honored scientists are saying after testing BRILACIDIN in the labs or you can belive the unsubstantiated claims of the other side. The agenda of the first group is to better society and bring help to the medical community. I can't say what the agenda is of the other side. God only knows..
BRILACIDIN *426* the SAFE ALTERNAIVE to many future ailments...
Recent GILD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 11:07:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 09:08:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:45:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:43:35 PM
- Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial • Business Wire • 09/12/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:41:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:38:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:33:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:23:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:20:53 PM
- Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies • Business Wire • 09/10/2024 12:00:00 PM
- Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer • Business Wire • 09/05/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/29/2024 07:23:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/28/2024 08:18:35 PM
- Gilead Sciences to Present at Upcoming Investor Conferences • Business Wire • 08/21/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 06:23:44 PM
- Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA • Business Wire • 08/14/2024 05:59:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/13/2024 08:27:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 08:22:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:17:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:06:06 PM
- Gilead Sciences Announces Second Quarter 2024 Financial Results • Business Wire • 08/08/2024 08:02:00 PM
- U.S. Index Futures Drop, Signaling Ongoing Market Volatility; Oil Prices Stall • IH Market News • 08/08/2024 09:55:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 09:28:51 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM